Search Result

Isoforms Recommended:	DYRK1

Results for "

DYRK1B

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (2) CDK (4) DYRK (18) GSK-3 (1) Ligands for Target Protein for PROTAC (1) Small Interfering RNA (siRNA) (1)
By Research Areas:	Cancer (17) Metabolic Disease (2) Neurological Disease (3)
Click Chemistry:	Alkynes (1)
Oligonucleotides:	Pre-designed siRNA Sets (1) siRNAs (1)

Inhibitors & Agonists

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12838

RO5454948 1 Publications Verification Mirk-IN-1; DYRK1B/A-IN-1	DYRK	Cancer
Mirk-IN-1 (Dyrk1B/A-IN-1) is a highly efficient and selective inhibitor of Dyrk1B and Dyrk1A, with IC50 values of 68 and 22nM respectively.

HY-117391

*AZ-Dyrk1B-33* 1 Publications Verification	DYRK	Metabolic Disease Cancer
AZ-Dyrk1B-33 is a potent and selective Dyrk1B kinase inhibitor, with an IC₅₀ of 7 nM ^[1].

HY-12277

AZ191 4 Publications Verification	DYRK	Cancer
AZ191 is a potent inhibitor that selectively inhibits *DYRK1B* with IC₅₀ of 17 nM ^[1].

HY-108476

INDY 2 Publications Verification	DYRK	Cancer
INDY is a potent and ATP-competitive *Dyrk1A* and *Dyrk1B* inhibitor with IC₅₀s of 0.24 μM and 0.23 μM, respectively. INDY binds in the ATP pocket of the enzyme and has a K_i value of 0.18 μM for Dyrk1A. INDY sharply reduces the self-renewal capacity of normal and tumorigenic cells in primary Glioblastoma (GBM) cell lines and neural progenitor cells ^[1] .

HY-RS04097

DYRK1B Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
DYRK1B Human Pre-designed siRNA Set A contains three designed siRNAs for DYRK1B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

DYRK1B Human Pre-designed siRNA Set A DYRK1B Human Pre-designed siRNA Set A

HY-108475

ProINDY	DYRK	Cancer
ProINDY, a prodrug of INDY (HY-108476), is a *DYRK1A* and *DYRK1B* inhibitor. ProINDY effectively recovers Xenopus embryos from head malformation induced by Dyrk1A overexpression ^[1].

HY-144614

JH-XVII-10	DYRK Apoptosis	Neurological Disease Cancer
JH-XVII-10 is a potent, selective and orally active *DYRK1A* and *DYRK1B* inhibitor with IC₅₀s of 3 nM and 5 nM for *DYRK1A* and *DYRK1B*, respectively. JH-XVII-10 shows antitumor efficacy in neck squamous cell carcinoma (HNSCC) cell lines ^[1].

HY-119607

DYRKi	DYRK	Cancer
DYRKi is an inhibitor of *DYRK1* and *DYRK1B* with IC₅₀ values of 3.7 µM and 90 nM, respectively, which is used as a potent antagonist of Hh/Gli signaling. DYRKi impairs SMO-dependent and SMO-independent oncogenic GLI activity in human medulloblastoma cells. DYRKi is promising for research of HH/GLI-associated cancers ^[1].

HY-146337

Dyrk1A/B-IN-1	DYRK	Cancer
Dyrk1A/B-IN-1 (compound 3n) is a potent, selective and cell-permeable *DYRK1A* and *DYRK1B* inhibitor with K_is of 67.8 nM and 237.9 nM, and IC₅₀s of 1.1 μM and 0.8 μM, respectively. Dyrk1A/B-IN-1 is not toxic to human cells. Dyrk1A/B-IN-1 can be used for researching DYRK1A and DYRK1B cellular functions and their role in pathologies ^[1].

HY-128759

DYRKs-IN-2	DYRK	Cancer
DYRKs-IN-2 (Example 132) is a potent *DYRKs* inhibitor with IC₅₀s of 30.6 nM and 12.8 nM for DYRK1B and DYRK1A, respectively. DYRKs-IN-2 has antitumor activity ^[1].

HY-128758

DYRKs-IN-1	DYRK	Cancer
DYRKs-IN-1 is a potent *DYRKs* (Dual-specificity tyrosine-phosphorylation-regulated kinases) inhibitor with IC₅₀s of 5 nM and 8 nM for DYRK1A and DYRK1B, respectively. DYRKs-IN-1 has antitumor activity ^[1] .

HY-111380

EHT 1610 1 Publications Verification	DYRK	Neurological Disease
EHT 1610 is a potent inhibitor of *DYRK, with IC₅₀s* of 0.36 nM (DYRK1A), 0.59 nM (DYRK1B), respectively. EHT 1610 exhibits antileukemia effect, regulates cell cycle and induces cell apoptosis ^[1] ^- .

HY-128758A

DYRKs-IN-1 hydrochloride	DYRK	Cancer
DYRKs-IN-1 hydrochloride is a potent *DYRKs* (Dual-specificity tyrosine-phosphorylation-regulated kinases) inhibitor with IC₅₀s of 5 nM and 8 nM for DYRK1A and DYRK1B, respectively. DYRKs-IN-1 hydrochloride has antitumor activity ^[1] .

HY-77324S

4-(Trifluoromethyl)aniline-d4 4-Aminobenzotrifluoride-d₄	DYRK	Cancer
4-(Trifluoromethyl)aniline-d₄ is deuterium labeled 4-(Trifluoromethyl)aniline. 4-(Trifluoromethyl)aniline is a DYRK1A and DYRK1B kinase inhibitor with IC50s of 54.84 nM and 186.40 nM, respectively[1].

HY-144617

JH-XIV-68-3	DYRK	Cancer
JH-XIV-68-3 is a selective macrocyclic inhibitor of *DYRK1A/B. JH-XIV-68-3 displays selectivity for DYRK1A and close family member DYRK1*B in biochemical and cellular assays. JH-XIV-68-3 demonstrates antitumor efficacy in head and neck squamous cell carcinoma (HNSCC) cell lines ^[1].

HY-111379

EHT 5372	DYRK CDK GSK-3	Neurological Disease Metabolic Disease Cancer
EHT 5372 is a highly potent and selective inhibitor of *DYRK's* family kinases with IC₅₀s of 0.22, 0.28, 10.8, 93.2, 22.8, 88.8, 59.0, 7.44, and 221 nM for *DYRK1A, DYRK1B, DYRK2, DYRK*3, CLK1, CLK2, CLK4, GSK-3α, and GSK-3β, respectively ^[1] .

HY-155723

Leucettinib-92	CDK DYRK	Others
Leucettinib-92 (compound 92) is an inhibitor of DYRK/CLK kinase, The IC₅₀s are 147 nM (CLK1), 39 nM (CLK2), 5.2 nM (CLK4), 0.8 μM (CLK3), 124 nM (DYRK1A), 204 nM (DYRK1B), 0.16 μM (DYRK2), respectively. 1.0 μM (DYRK3), 0.52 μM (DYRK4), 2.78 μM (GSK3) ^[1].

HY-112296

T025 2 Publications Verification	CDK Apoptosis DYRK	Cancer
T025 is an orally active and highly potent inhibitor of Cdc2-like kinase (CLKs), with K_d values of 4.8, 0.096, 6.5, 0.61, 0.074, 1.5 and 32 nM for CLK1, CLK2, CLK3, CLK4, DYRK1A, DYRK1B and DYRK2, respectively. T025 induces caspase-3/7-mediated cell apoptosis. T025 reduces CLK-dependent phosphorylation. T025 exerts anti-proliferative activities in both hematological and solid cancer cell lines (IC₅₀ values: 30-300 nM). T025 has an anti-tumor efficiency, mainly for MYC-driven disease research ^[1].

HY-168196

DYR684m	Ligands for Target Protein for PROTAC	Cancer
DYR530-Boc is a target protein ligand activity control that can be used to synthesize PROTAC (HY-168194) ^[1].

HY-115470

CLK-IN-T3 1 Publications Verification	CDK DYRK	Cancer
CLK-IN-T3 is a high potent, selective, and stable CDC-like kinase (CLK) inhibitor with IC₅₀s of 0.67 nM, 15 nM, and 110 nM for CLK1, CLK2, and CLK3 protein kinases, respectively. CLK-IN-T3 has anti-cancer activity ^[1].

4-(Trifluoromethyl)aniline-d4
4-(Trifluoromethyl)aniline-d₄ is deuterium labeled 4-(Trifluoromethyl)aniline. 4-(Trifluoromethyl)aniline is a DYRK1A and DYRK1B kinase inhibitor with IC50s of 54.84 nM and 186.40 nM, respectively[1].

Cat. No.	Product Name		Classification

HY-168196

DYR684m		Alkynes
DYR530-Boc is a target protein ligand activity control that can be used to synthesize PROTAC (HY-168194) ^[1].

DYRK1B Human Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
DYRK1B Human Pre-designed siRNA Set A contains three designed siRNAs for DYRK1B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.